inhibitors are particularly effective in this group of patients.
The company notes that allowance of this patent further enhances the strategic development of a broad intellectual property estate surrounding patented core technology based upon vaccine formulations comprising Proteosome
They were able to partially restore ATRA sensitivity in the ATRA-resistant NB4 cells by proteosome
inhibitors by blocking the degradation of the fusion receptor protein.
ID Biomedical is a North American based biotechnology company focused on the development of proprietary subunit vaccine products, including those based on its Proteosome
platform intranasal adjuvant/delivery technology.
The first poster, titled "Reovirus synergy with proteosome
inhibitor carfilzomib and Akt inhibitor perifosine overcomes therapy resistance of multiple myeloma: promising preclinical activity," is being presented by Thirukkumaran et al.
Combination studies with GX15-070 demonstrated that it enhanced the anti-myeloma activity stimulated by melphalan, dexamethasone, and bortezomib, a proteosome
This platform technology has led to the discovery of a lead tumor activated proteosome
inhibitor and a lead tumor activated doxorubicin for treatment of a range of cancers.
The phosphorylated PTEN (p-PTEN) is less susceptible to degradation by the proteosome
but is less active.
technology, which was initially invented at the Walter Reed Army Institute of Research, has been specifically designed to create nasal vaccines that elicit protective immune responses at the mucosal surfaces which line the respiratory tract including the nose, throat and lungs.
Gemin X announced today the initiation of a Phase 1/2 clinical trial of GX15-070 in combination with docetaxel (Taxotere[R]), a chemotherapeutic agent, in patients with non-small cell lung cancer (NSCLC), and a Phase 1 trial in combination with bortezomib (Velcade[R]), a proteosome
inhibitor, in patients with mantle cell lymphoma (MCL).
3 MLN 9708 (Takeda), First Oral Proteosome
Inhibitor to Reach Clinical Trials
2 Johnson & Johnson (Janssen): Proteosome
Inhibitor and mAb Leader?